Technical Monitor. The CONTRACTOR designated individual(s) representing the end user of the Order. May be the same individual as the ‘hiring manager’ requiring services or an intermediary managing the work outlined in the Order. This person is necessary for the successful performance of the Order and is accountable for stewardship of the Subcontractor’s technical performance. REVISION:
Technical Monitor means an advisor to the Contracting Officer on the technical performance of the contract.
Technical Monitor. HReynolds Status: Complete Group: HSR Objective(s): To examine whether offering the infant dose of nevirapine to take home increases uptake. Description: Assuming the infant dose is important to prevent MTCT, this study will examine whether offering the infant dose to take home increases uptake. This study is more descriptive in nature, although we propose to employ a non-randomized post-test only, control group design. Comparing the current standard of care (infants get their NVP dose at the facility within 72 hours) with the new strategy (to give the dose to the mothers to administer at home), the study seeks to measure the proportion of HIV+ pregnant women in antenatal care (ANC) who received the infant take home NVP dose and the proportion of women who give the infant dose. To implement the study, we are working in sites supported by FHI, and providers systematically fill and distribute the infant dose to all women greater than or equal to 32 weeks gestation in a subset of facilities. We are collaborating with PATH on this project who has developed packaging material for the infant dose. Another subset of women in matched facilities will serve as the control group. We will follow up women in the training group at home to interview them about their experiences with the infant NVP dose. In the control group, we will also follow up HIV- infected women who attend ANC at greater than or equal to 32 weeks to understand the factors that facilitated them to take their infant for the dose at the facility or not. We will compare the proportion of women whose infants received the NVP dose between the two groups. We will also be able to investigate the factors associated with NVP use or non-use. The major limitation of the study is we rely on women’s reports. This activity was approved for spending and continue as a no-cost extension activity of the CTR through August 31, 2006. 2005—06 ANNUAL REPORT Activities, Accomplishments, Problems through December 31, 2005 • The protocol was prepared, reviewed, and approved by FHI’s PHSC on November 11, 2005. • Data collection instruments were finalized in December 2005. Activities, Accomplishments, Problems between January 1, 2006—June 30, 2006 • Xxxxxxxx National Hospital’s Ethical Review Committee approved the study in February 2006. • The consultant was hired in February 2006. • Research assistants were trained during March 2006. • FHI staff traveled to study sites in April 2006 to train providers in infant nevirapine do...
Examples of Technical Monitor in a sentence
Any security system the Subcontractor may elect to use (fences, keys, alarms, etc.) must be coordinated with the NREL Technical Monitor.
The Subcontractor is responsible to advise the NREL Technical Monitor promptly of any non-routine events, occurrences, incidents, accidents, etc., particularly in situations involving lost–time accidents and ambulance runs, occurring under this subcontract.
The Subcontractor is responsible to coordinate with the NREL Technical Monitor all vehicle parking requirements needed to perform the subcontract work on the NREL operated facilities.
The Government may designate the M&O Contractor to be the Technical Monitor for any right, duty or interest in this Contract.
It is the Subcontractor’s responsibility to obtain and provide all necessary information and documentation to meet NREL, DOE, and federal requirements regarding Subcontractors’ employees (or its lower-tier Subcontractors’ employees), officers’, and agents’ work authorization and identification to the NREL Technical Monitor and the NREL Subcontract Administrator to meet the appropriate time frames for NREL Security to process and approve the request for access.
More Definitions of Technical Monitor
Technical Monitor. SHamel Status: Ongoing Group: PQC USAID Intermediate Outcome: IR3 = Use of Contraceptives, Microbicides and Reproductive Health Technologies Optimized and Expanded Strategy Outcome: Production surveillance and compliance testing routinely conducted and capacity expanded to support offshore procurement of products used in family planning and HIV/AIDS prevention programs Objective(s): To ensure pre-distribution quality of condoms procured domestically and offshore by USAID for developing country programs.
Technical Monitor. ERaymond Status: Ongoing Group: CRD USAID Intermediate Outcome: IR1 = Improved and New Contraceptive and Reproductive Health Technologies Developed, Evaluated and Approved. Strategy Outcome: Critical questions regarding the long term safety and benefit of hormonal contraceptives identified, and at least one high priority question addressed through research Objective(s): To determine whether or not the proposed randomized trial is feasible, and if so, to develop a plan for implementing the study. Description: Data from several recent observational studies have suggested that use of progestin-only contraceptive methods may increase the risk of acquisition of sexually transmitted infections (STIs), including chlamydia (CT), gonorrhea ( GC), and HIV. However, this conclusion is suspect because of possible failure to control adequately for selection bias and confounding. For example, a higher rate of risky behaviors among progestin-only method users than among non- users could result in an apparent but false association between method use and infection. Considering the public health importance of both progestin-only methods and STIs, clarification of this issue is urgently needed. In addition, the role of herpes simplex virus (HSV) infection in mediating an increased HIV risk associated with depot medroxyprogesterone acetate (DMPA), as suggested in one recent study, needs further evaluation. The best way to provide this clarification would be through a randomized trial. This subproject will support activities aimed at assessing the feasibility of a randomized trial to investigate the effects of DMPA on the incidence of GC and CT and possibly HSV, and if feasible, support the application to other donors for funding to implement the trial. Anticipated activities may include: developing the trial protocol; selecting study sites which will require surveys at multiple locations to assess the feasibility of recruitment and the incidence of GC/CT/HSV in prospective trial populations, and visits to sites that seem promising; and investigating sources of funding for the trial.
Technical Monitor. CMorrison Status: Complete Group: CRD Objective(s): To compare the expression of human beta-defensins (hBDs) from the genital tract of HIV-infected women and HIV-seronegative women at moderate to high risk of HIV-1 infection in Uganda and Zimbabwe in order to evaluate a potential correlation between expression of hBDs in the cervix/vagina and transmission of HIV-1. The secondary objective of this subproject is to analyze the potential effect of hormonal contraception and pregnancy in the expression of hBDs in the genital tract of women from the Ugandan and Zimbabwean cohort and how this may correlate to protective immunity against HIV at the mucosal level. Description: For the primary objective, both cross-sectional and longitudinal studies will be performed using samples from the HC-HIV study (FCO 502). In the HC-HIV study, 4500 women were tested for HIV-1 seroconversion every three months and samples were taken. Plasma swabs of endocervical or vaginal mucosa have been stored in a repository. In addition, demographic and sexual behavior information and testing for pregnancy, sexually transmitted diseases and cervical ectopy have been obtained longitudinally. Vaginal and cervical swabs will be obtained from four groups of HIV-infected women based on CD4+ T-cell counts (i.e.,< 50; 50- 199; 200-500; and >500 cells/ l), with no restrictions in their HIV RNA plasma level. Ten HIV- infected women will be included in each group for a total of 40 samples. Cervical and vaginal swabs from 40 HIV-seronegative women at moderate to high risk for HIV-1 infection will also be evaluated. For the secondary objective, samples will be obtained from three different contraceptive groups:
Technical Monitor. XXxxx Status: Ongoing Group: HSR USAID Intermediate Outcome: IR3 = Use of Contraceptives, Microbicides and Reproductive Health Technologies Optimized and Expanded Strategy Outcome: At least three scalable and appropriate models given the CPR, HIV prevalence, and available services for integrating family planning and HIV services designed, evaluated and introduced in up to five countries. Objective(s): 1) To explore with providers and clients the feasibility and acceptability of alternative strategies for linking FP services to PMTCT services; and 2) to measure how such linkages affect FP uptake among women who have completed PMTCT services. Description: South Africa’s National Department of Health has given priority to providing Prevention of Maternal to Child Transmission (PMTCT) services to prevent HIV infections. Even though South Africa’s national service delivery guidelines advocate the provision of FP in the PMTCT package of care, few efforts have been made to integrate the two services. To address this issue, FHI proposes a two-phase study. Phase I will consist of formative research. Interviews with PMTCT clients in 6 sites will assess the priority they place on preventing or delaying a future pregnancy and will explore their interest in receiving FP services under different service delivery configurations e.g. during antenatal care, post-partum visits, immunization and well baby check-ups. Providers and facility supervisors of each of these services will also be interviewed to assess their willingness to take on the added responsibility of providing FP services. Results of data collection will be shared with program managers, who will identify one or two integration interventions that appear to be the most feasible. Phase II will consist of operations research to test the selected interventions. It is anticipated that for each intervention, five matched pairs of PMTCT sites will be identified to participate. At baseline, PMTCT clients consenting to be re-contacted will be interviewed to assess their current contraceptive use. For each of the five matched pairs of PMTCT sites, one site will be randomly assigned to receive the intervention and the other site will continue delivering PMTCT as usual. After a 6-month follow-up period, another cross-section of PMTCT clients will be interviewed. Process data will also be collected to assess the extent to which the intervention was implemented as intended. Finally, the cost of implementing the intervention...
Technical Monitor. WCastro Status: Ongoing Group: FITS USAID Intermediate Outcome: IR3 = Use of Contraceptives, Microbicides and Reproductive Health Technologies Optimized and Expanded Strategy Outcome: Evidence-based technical assistance, curricula and tools provided to at least three field programs per year to implement, expand and improve integrated FP and HIV programs
Technical Monitor. JKimani Status: Ongoing Group: FITS USAID Intermediate Outcome: IR3 = Use of Contraceptives, Microbicides and Reproductive Health Technologies Optimized and Expanded Strategy Outcome: Research evidence provided to at least four countries to inform policy reviews and strengthen policies focused on increasing contraceptive use in HIV programs to avert HIV-positive births International recommendations, country-specific guidelines, and program documents for contraceptive use by people at risk of HIV and HIV-infected, including women on ART changed or strengthened Objective(s): To disseminate country-specific, evidence-based information on the relationship between hormonal contraceptive use and HIV acquisition to Kenyan stakeholders in the Ministry of Health (MOH), family planning and HIV/AIDS organizations, family planning and VCT service providers, and the media. Description: FHI assistance for this subproject to disseminate evidence-based information on hormonal contraception and HIV was requested by the Kenyan MOH. USAID/Kenya has provided funding to support its implementation. This subproject targets a CRTU enhanced country and leverages knowledge management products on this topic being developed under a complementary subproject.
Technical Monitor. EMcGinn Status: Complete Group: FITS USAID Intermediate Outcome: IR3 = Use of Contraceptives, Microbicides and Reproductive Health Technologies Optimized and Expanded Strategy Outcome: Strategies to enhance correct use and reduce discontinuation of hormonal methods developed and evaluated Objective(s): To focus discussion on the topic of hormonal contraceptive discontinuation and help partners develop a consensus about research and research-to-practice priorities to improve continuation.